These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. In vivo cancer vaccination: Which dendritic cells to target and how? Chiang CL; Kandalaft LE Cancer Treat Rev; 2018 Dec; 71():88-101. PubMed ID: 30390423 [TBL] [Abstract][Full Text] [Related]
5. Cancer, aging and immunotherapy: lessons learned from animal models. Lustgarten J Cancer Immunol Immunother; 2009 Dec; 58(12):1979-89. PubMed ID: 19238382 [TBL] [Abstract][Full Text] [Related]
6. Considerations for successful cancer immunotherapy in aged hosts. Hurez V; Padrón ÁS; Svatek RS; Curiel TJ Clin Exp Immunol; 2017 Jan; 187(1):53-63. PubMed ID: 27690272 [TBL] [Abstract][Full Text] [Related]
10. Dendritic cell immunotherapy for the treatment of neoplastic disease. Decker WK; Xing D; Shpall EJ Biol Blood Marrow Transplant; 2006 Feb; 12(2):113-25. PubMed ID: 16443510 [TBL] [Abstract][Full Text] [Related]
11. Chemical Strategies to Enhance the Therapeutic Efficacy of Toll-like Receptor Agonist Based Cancer Immunotherapy. Lee SN; Jin SM; Shin HS; Lim YT Acc Chem Res; 2020 Oct; 53(10):2081-2093. PubMed ID: 32966047 [TBL] [Abstract][Full Text] [Related]
16. Dendritic cell-based cancer immunotherapies. Fujii S; Takayama T; Asakura M; Aki K; Fujimoto K; Shimizu K Arch Immunol Ther Exp (Warsz); 2009; 57(3):189-98. PubMed ID: 19479202 [TBL] [Abstract][Full Text] [Related]
17. Promising preclinical platform for evaluation of immuno-oncology drugs using Hu-PBL-NSG lung cancer models. Pyo KH; Kim JH; Lee JM; Kim SE; Cho JS; Lim SM; Cho BC Lung Cancer; 2019 Jan; 127():112-121. PubMed ID: 30642538 [TBL] [Abstract][Full Text] [Related]
18. Dendritic cell preparation for immunotherapeutic interventions. Simon T; Fonteneau JF; Grégoire M Immunotherapy; 2009 Mar; 1(2):289-302. PubMed ID: 20635946 [TBL] [Abstract][Full Text] [Related]
19. Immunotherapy of tumors with recombinant adenovirus encoding macrophage inflammatory protein 3beta induces tumor-specific immune response in immunocompetent tumor-bearing mice. Hou JM; Zhao X; Tian L; Li G; Zhang R; Yao B; Deng HX; Yang JL; Wei YQ Acta Pharmacol Sin; 2009 Mar; 30(3):355-63. PubMed ID: 19262559 [TBL] [Abstract][Full Text] [Related]
20. Immune based therapies in cancer. Krüger C; Greten TF; Korangy F Histol Histopathol; 2007 Jun; 22(6):687-96. PubMed ID: 17357098 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]